Date |
Company |
Amount |
Funding type |
Investors |
Therapeutic area |
Type of Information |
2016-09-22 |
iOmx Therapeutics (Germany) |
€ 40 million |
series A financing round |
Merck Ventures (Germany) MPM Capital (USA - MA) Sofinnova Partners (France) Wellington Partners (UK) |
Cancer - Oncology |
Series A financing round |
2016-09-21 |
Artios Pharma (UK) |
£25million ($33.2million) |
series A financing round |
SV Life Sciences (UK - USA) Merck Ventures (Germany) Imperial Innovations (UK) Arix Bioscience (UK) CRT Pioneer Fund (managed by Sixth Element) AbbVie Ventures (USA) |
Cancer - Oncology |
Series A financing round |
2016-09-20 |
CxCOG consortium (Theranexus, Synerlab Developpement, Lille University Hospital) (France) |
€ 3.2 million ($ 3.6 million) |
grant |
FUI (Fond Unique Interministériel - a French program supporting collaborative research projects)(France |
Neurodegenerative diseases |
Grant |
2016-09-20 |
Agios Pharmaceuticals (USA - MA) |
$173 million |
private placement |
|
Cancer - Oncology - Rare diseases |
Private placement |
2016-09-15 |
Eyevensys (France) |
€ 9 million |
series A financing round |
Boehringer Ingelheim Venture Fund (Germany), Pontifax Venture Capital (Israel) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Series A financing round |
2016-09-14 |
Theradiag (France) |
€ 2.5 million |
capital increase |
HOB Biotech (China) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Diagnostic |
Capital increase |
2016-09-12 |
Angionetics (USA - CA) |
$3 million (€2.7 milion) |
equity investment |
Huapont Life Sciences (China) |
Cardiovascular diseases |
Fundraising |
2016-09-12 |
Advantagene (USA - MA) |
$14.2 million |
series A financing round |
National Securities Corporation (USA - NY) |
Cancer - Oncology |
Series A financing round |
2016-09-08 |
Avexis (USA - IL) |
$127.7 million (€ 113.6 million) |
private placement |
|
Rare diseases - Genetic diseases - Neurological diseases |
Private placement |
2016-09-01 |
OncoDNA (Belgium) |
€ 7.7 million |
financing round |
IPG/bio.be (Belgium) Invest4OncoDNA (Belgium) Sambrinvest (Belgium) Vinsovier (Belgium) Sofinim NV (Belgium) SRIW (Belgium) CPH (Belgium) Inventures (USA - CA) |
Cancer - Oncology |
Financing round |
2016-08-30 |
Santhera Pharmaceuticals (Switzerland) |
$ 246,000 |
grant |
FDA (USA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Grant |
2016-08-23 |
OncoMed Pharmaceuticals (USA - CA) |
$59.2 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-08-12 |
Arrowhead Pharmaceuticals (USA - CA) |
$45 million |
private placement |
Orbimed (USa - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) other institutional investors |
|
Private placement |
2016-08-11 |
Tapimmune (USA - Fl) |
$8.5 million (€7.6 millio) |
private placement |
|
Cancer - Oncology |
Private placement |
2016-08-10 |
Avacta (UK) Leeds University (UK) |
£3.8 million (€ 4.4 million) |
grant |
Medical Research Council (UK) |
Infectious diseases - Diagnostic |
Grant |
2016-08-10 |
Epigenomics (Germany - USA) |
|
IPO |
|
Cancer - Oncology - Diagnostic |
IPO |
2016-08-10 |
Gemphiire Therapeutics |
$30 million |
IPO |
|
Liver diseases - Hepatic diseases |
IPO |
2016-08-09 |
CEL-SCI Corporation (USA -VA) |
$5 million |
private placement |
|
Cancer - Oncology |
Private placement |
2016-08-09 |
Y-mAbs Therapeutics (USA - NY) |
$ 25 million |
seed financing round |
|
Cancer - Oncology |
Financing round |
2016-08-09 |
Biomarin (USA - CA) |
|
private placement |
|
|
Private placement |